Crossed in Medical Technology
Navigation Links
Crossed in Medical Technology
... censored analysis excluding patients after they crossed over to Femara, reduction in risk of death was ... 25% of patients in the tamoxifen arm selectively crossed over to Femara therapy after the tamoxifen arm ... one quarter of those patients selectively crossed over to Femara treatment. The other three ...
... maintenance treatments every 8 weeks. Patients in the placebo group were crossed over at week 24 to receive REMICADE 5 mg/kg at weeks 24, 26 and 30, then ... during the induction phase. Patients in the placebo group were crossed over at week 16 to receive REMICADE 5 mg/kg at weeks 16, 18 and 22, then ...
... were randomized to a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200, 300 or 400 mg). Four weeks later, they were crossed over to a second single picoplatin dose administered via the alternative route. In the second part of the trial, patients received only a single oral ...
... support for its potential as a promising therapeutic to treat this devastating disease." Patients originally on placebo for 12 months who were then crossed over to Dimebon in the open-label extension phase stabilized across all key measures tested. Since these patients had declined over the previous ...
... planned to begin later this year. Data were also presented from preclinical studies which demonstrated that systemically administered MSI-1436 crossed the blood-brain barrier and functionally inhibited PTP1B in the hypothalamus. In this study, rats were administered a single dose of MSI-1436 one day ...
... Health System, Lake Success, NY, and Associate Professor of Medicine, New York University School of Medicine. "We observe that patients who crossed over from placebo to belimumab after Week 52 have also shown improvement across multiple clinical measures. The durability of clinical effect and the ...
... Injectable Suspension product (contains no Cremophor). In addition, 4 of the patients treated initially with the Injection formulation crossed over to receive the Injectable Suspension formulation. -- For the Injection product: 18 were evaluable and 11 responded (4 PR, 4 ...
... to receive ustekinumab received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks. Patients in the placebo group crossed over to receive either 45 mg or 90 mg doses of ustekinumab at weeks 12 and 16 and every subsequent 12 weeks. The primary end point of the study was ...
... of response was 17 weeks. In the BSC group 174 (75 percent) patients received Vectibix under the crossover protocol. In those patients that crossed over, the objective response rate was 10 percent. The median time to crossover was 7.0 (6.6, 7.3) weeks. The median follow-up after crossover was 27 ...
... additional 21 blood plasma samples were collected after dosing over a period of 36 hours. After a washout period of eight days, each participant was crossed over to receive the alternate tablet, and plasma samples were collected according to the same schedule. A total of 28 subjects completed both arms of ...
... in disease activity score on the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20) at week 24. At week 24, placebo patients were crossed over to receive treatment with REMICADE 5 mg/kg at weeks 0, 2 and 6 and every six weeks thereafter and continued on REMICADE through the remainder ...
Diverse Approaches to Alzheimer's Therapies Continue to Show Progress at ICAD
... the study. Patients originally on placebo for 12 months who were then crossed over to Dimebon on the OLE phase also stabilized across all key measures ... depressed mood/sadness. "People initially treated with placebo and then crossed over to Dimebon did not show the same level of benefit as those people who ...... maintenance treatments every 8 weeks. Patients in the placebo group were crossed over at week 24 to receive REMICADE 5 mg/kg at weeks 24, 26 and 30, then ... during the induction phase. Patients in the placebo group were crossed over at week 16 to receive REMICADE 5 mg/kg at weeks 16, 18 and 22, then ...
Schering-Plough Announces Results of the Early ACS Trial
... not administered pre-PCI, the initial infusion was continued unchanged for 18-24 hours post-PCI. If a thrombotic complication occurred after the wire crossed the lesion, investigators could request a bailout PCI kit containing bolus therapy opposite to initial treatment assignment. For patients ...Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
... first-in-human clinical trial for the vProtect(TM) Luminal Shield, conducted at the Corbic Research Institute in Colombia. The Shield successfully crossed all target lesions and was safely implanted in all 30 patients, with a technical success rate of 100%. No procedural or in-hospital complications ...... were randomized to a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200, 300 or 400 mg). Four weeks later, they were crossed over to a second single picoplatin dose administered via the alternative route. In the second part of the trial, patients received only a single oral ...
... support for its potential as a promising therapeutic to treat this devastating disease." Patients originally on placebo for 12 months who were then crossed over to Dimebon in the open-label extension phase stabilized across all key measures tested. Since these patients had declined over the previous ...
... planned to begin later this year. Data were also presented from preclinical studies which demonstrated that systemically administered MSI-1436 crossed the blood-brain barrier and functionally inhibited PTP1B in the hypothalamus. In this study, rats were administered a single dose of MSI-1436 one day ...
... Health System, Lake Success, NY, and Associate Professor of Medicine, New York University School of Medicine. "We observe that patients who crossed over from placebo to belimumab after Week 52 have also shown improvement across multiple clinical measures. The durability of clinical effect and the ...
... Injectable Suspension product (contains no Cremophor). In addition, 4 of the patients treated initially with the Injection formulation crossed over to receive the Injectable Suspension formulation. -- For the Injection product: 18 were evaluable and 11 responded (4 PR, 4 ...
Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
... to receive ustekinumab received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks. Patients in the placebo group crossed over to receive either 45 mg or 90 mg doses of ustekinumab at weeks 12 and 16 and every 12 weeks thereafter. The primary endpoint of the study was ...... to receive ustekinumab received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks. Patients in the placebo group crossed over to receive either 45 mg or 90 mg doses of ustekinumab at weeks 12 and 16 and every subsequent 12 weeks. The primary end point of the study was ...
... of response was 17 weeks. In the BSC group 174 (75 percent) patients received Vectibix under the crossover protocol. In those patients that crossed over, the objective response rate was 10 percent. The median time to crossover was 7.0 (6.6, 7.3) weeks. The median follow-up after crossover was 27 ...
... additional 21 blood plasma samples were collected after dosing over a period of 36 hours. After a washout period of eight days, each participant was crossed over to receive the alternate tablet, and plasma samples were collected according to the same schedule. A total of 28 subjects completed both arms of ...
... in disease activity score on the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20) at week 24. At week 24, placebo patients were crossed over to receive treatment with REMICADE 5 mg/kg at weeks 0, 2 and 6 and every six weeks thereafter and continued on REMICADE through the remainder ...
Eurand's Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
... dose titration, patients were randomized to receive Zentase or placebo over a week-long period. Following open-label normalization, all patients were crossed over to the alternative treatment arm. A determination of CFA and CNA on a 72-hour sample and under controlled diet in a hospital environment was ...Avian (Bird) Flu: Is There a Role for Rapid Tests?
... First in 1997 and now recently, some humans in close contact with infected birds have contracted the virus. Now that the H5N1 subtype has crossed the species barrier to humans, there is concern for human-to-human transmission. Given the presumed paucity of human resistance to the H5N1 subtype, ...Other ContentspinwormspinwormdwarfismplaceboplaceboplaceboplacebopreviapreviaOther Tagshighlighthighlighthighlighthighlight
(Date:11/23/2009)... CHAMPAIGN, Ill. A new study provides "incontrov... of Toba on the island of Sumatra about 73,000 yea...0 miles from the epicenter, researchers report. ,...eters of ash into the atmosphere, leaving a crater...00 kilometers long and 35 kilometers wide. Ash fro...
(Date:11/23/2009)..., BIRMINGHAM, Ala. A new study by University of...t body-mass index (BMI) and co-existing medical co...ed survival observed among African-Americans compa...study is published online Nov. 23 in Cancer , a j...ding indicates that although BMI and co-morbidity ...
(Date:11/23/2009)...CORVALLIS, Ore. A string of recent discoveries ab...renewed interest in this multi-purpose nutrient, i...ho are deficient in it, spurred research and even ...ic." , On issues ranging from the health of your...even vulnerability to influenza, vitamin D is now ...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 1Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 2Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 3Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 4Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 1Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 2(Date:11/25/2009)...ors often plagued by neurological symptoms, study ... News) -- Neurological side effects are among the ... testicular cancer who were treated with cisplatin...he study included 1,409 Norwegian men treated for ... who took part in a follow-up survey conducted fro...
(Date:11/25/2009)..., LittleImprovementShownforthe4thStraightYear ...Today,LungCancerAlliance-Georgia(LCA-GA)issuedthe ...essmentofprogressbeingmadeagainstthislethaldisease...liance(LCA),theonlynationalorganizationdedicatedex...gwithoratriskforlungcancer. ,, (Logo: http://ww...
(Date:11/25/2009)...e, disks placed under the skin kill tumor cells, s...hDay News) -- A cancer vaccine delivered in a fing...mice, a new study reports. , The method uses po... loaded with tumor-specific antigens and implanted...attack tumors. The Harvard University scientists w...
(Date:11/25/2009)... BioSpace.com, the premier reso...eiled the third edition of the BioForest™ Ho... Englewood, CO (Vocus) November 25, 2009 -- Bi...careers and information, unveiled the third editio...ning., , , , ,This regional campaign is a promoti...
(Date:11/25/2009)..., SALTLAKECITY,Nov.25/PRNewswire/--dazzlesmile,llc...ww.optimalhealthscience.com havefileda67-pagefeder...ogle.com,Inc.,JesseWillms,FarendServicesLimited,an...heUnitedStatesDistrictCourtfortheDistrictofUtah,al...dazzlesmile(TM)brandedteethwhiteningproducts,viola...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2[0] Long-Term Problems Linked to Testicular Cancer Chemo[0] Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer[2] Implantable Cancer Vaccine Shows Promise[1] BioSpace Showcases Leading Life-Science Companies in the Northwest[0] dazzlesmile Sues Epic Advertising and Jesse Willms
hedgingMerrillbuilderdownplaysdiamondsRubyrearseligiblebackedhighlightrigorscaptivatedPretextingexpects
Other Tagspossible 2possible 3possible 4possible 5possible 6possible 7possible 8possible 9possible 10chicken 2chicken 3chicken 4chicken 5chicken 6chicken 7chicken 8chicken 9chicken 10from 2from 3from 4from 5from 6from 7from 8from 9from 10saving 2saving 3saving 4saving 5saving 6saving 7saving 8saving 9saving 10life 2life 3life 4life 5life 6life 7life 8life 9life 10death 2death 3death 4death 5death 6death 7death 8death 9death 10extra 2extra 3extra 4extra 5extra 6rewarding 2predicted 2predicted 3predicted 4predicted 5predicted 6predicted 7predicted 8predicted 9
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |